Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911859 | 0.93 | PRKDC (0.45) | SUV39H2PRKDCALDH1A1PDE10AHPGD | |
| SCHEMBL13849349 | 0.85 | ALDH1A1 (0.58) | SUV39H2PRKDCALDH1A1PDE10AHPGD | |
| SCHEMBL23153727 | 0.85 | LGMN (0.44) | PRKDCALDH1A1HPGDTSHRNPSR1 | |
| SCHEMBL24742953 | 0.82 | PRKDC (0.42) | PRKDCALDH1A1PDE10AHPGDAKR1C3 | |
| SCHEMBL4094752 | 0.81 | LGMN (0.46) | PRKDCALDH1A1PDE10AAKR1C3MAPT | |
| SCHEMBL23153812 | 0.79 | HTT (0.58) | ALDH1A1NPSR1MAPTCYP2C19SMN1; SMN2 | |
| SCHEMBL12385978 | 0.78 | POLB (0.48) | PRKDCALDH1A1HPGDNPSR1AKR1C3 | |
| SCHEMBL1911908 | 0.78 | LGMN (0.46) | PRKDCALDH1A1PDE10AAKR1C3MAPT | |
| SCHEMBL12046912 | 0.78 | ALDH1A1 (0.50) | PRKDCALDH1A1HPGDNPSR1AKR1C3 | |
| SCHEMBL20626398 | 0.77 | APP (0.44) | PRKDCALDH1A1PDE10AAKR1C3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | SUV39H2 2602/4885PRKDC 1273/4885ALDH1A1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.